We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazil’s Butantan Institute reported that Sinovac’s COVID-19 vaccine, CoronaVac, demonstrated an overall efficacy of only 50.38 percent in a phase 3 trial, putting it barely over the World Health Organization’s 50 percent efficacy threshold for approval. Read More
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. Read More
COVID-19 patients on intensive care support did not see improvement when given convalescent plasma, according to preliminary findings from the UK arm of a global trial. Read More
A phase 2 trial of Eli Lilly’s investigational Alzheimer’s drug donanemab demonstrated a “significant slowing of decline” in early Alzheimer’s patients who exhibited symptoms, the company revealed Monday. Read More
The UK’s National Health Service (NHS) will begin treating adult COVID-19 patients in intensive care with Roche’s and Sanofi’s arthritis medications following positive trial results that showed the drugs were highly effective when given early enough. Read More
Multiple COVID-19 vaccine developers are expected to file for regulatory approval in the coming months as the global pandemic continues its relentless advance. Read More
A study carried out by the University of Texas Medical Branch and Pfizer has found that the drugmaker’s COVID-19 vaccine still protects against a viral mutation that’s raised concerns around the world, though more research is needed. Read More
India’s Bharat Biotech has finalized enrollment for a phase 3 trial of its COVID-19 vaccine, Covaxin, which Indian regulators approved Jan. 3 for emergency use. Read More
A small randomized trial in Argentina has found that the early use of convalescent plasma in COVID-19-infected adults helped to reduce progression to severe disease. Read More
Scientists are closely monitoring the potential impact of mutations of the SARS-CoV-2 virus on the effectiveness of COVID-19 vaccines, but for the moment the new strains don’t appear able to completely evade their protective effect. Read More